Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents

Lambert, Thierry; Mégraud, Françis; Gerbaud, Guy; Courvalin, Patrice

doi:10.1128/aac.30.3.510

Cited by 106 publications

(45 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro, a number of antibiotics, including P-lactams, macrolides, and quinolones, have been known to be highly active against H. pylori (1,8,10,13,22,30,32,33,36). However, when tested as single agents in clinical studies, erythromycin (23), doxycycline (35), ofloxacin (5), ciprofloxacin (34), and norfloxacin (24) have not succeeded in eradicating H. pylori.…”

Section: Resultsmentioning

confidence: 99%

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Iwahi

Satoh

Nakao

et al. 1991

Antimicrob Agents Chemother

269

156

View full text Add to dashboard Cite

The activities of various types of antiulcer agents against Helicobacter pylori (formerly called Campylobacter pylon) strains were determined by an agar dilution method. Among the compounds tested, two benzimidazole proton pump inhibitors, lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 ,ug/ml, and fourfold more potent than that of omeprazole. A major metabolite and two acid-converted rearrangement products of lansoprazole also exhibited good activities comparable or superior to that of the parent compound. Exposure to lansoprazole of H. pylori growing in a liquid medium led to an extensive loss of viability without a reduction in culture turbidity and produced an aberrant bacterial morphology characterized by the irregular constriction of cells and the collapse of cell surface structures. The antibacterial activity of lansoprazole and its related compounds was selective against H. pylori; common aerobic and anaerobic bacteria and Campylobacterjejuni were not inhibited by 100 ,ug/ml.

show abstract

Section: Resultsmentioning

confidence: 99%

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Iwahi

Satoh

Nakao

et al. 1991

Antimicrob Agents Chemother

269

156

View full text Add to dashboard Cite

show abstract

“…Wild-type strains are susceptible to ␤-lactams (except cefsulodin), fosfomycin, macrolides, aminoglycosides, tetracyclines, chloramphenicol, rifampins, fluoroquinolones, 5-nitroimidazoles, and nitrofurans (289,355). With the exception of chloramphenicol (because of toxicity) and aminoglycosides (because of a lack of diffusion), they have all been used in H. pylori eradication regimes.…”

Section: Phenotypes Observedmentioning

confidence: 99%

Helicobacter pyloriDetection and Antimicrobial Susceptibility Testing

2007

View full text Add to dashboard Cite

SUMMARY The discovery of Helicobacter pylori in 1982 was the starting point of a revolution concerning the concepts and management of gastroduodenal diseases. It is now well accepted that the most common stomach disease, peptic ulcer disease, is an infectious disease, and all consensus conferences agree that the causative agent, H. pylori, must be treated with antibiotics. Furthermore, the concept emerged that this bacterium could be the trigger of various malignant diseases of the stomach, and it is now a model for chronic bacterial infections causing cancer. Most of the many different techniques involved in diagnosis of H. pylori infection are performed in clinical microbiology laboratories. The aim of this article is to review the current status of these methods and their application, highlighting the important progress which has been made in the past decade. Both invasive and noninvasive techniques will be reviewed.

show abstract

“…A variety of antimicrobial agents display good activity against C. pyloridis in vitro (1,5,8). Yet when tested as single agents in clinical studies, they do not succeed in eradicating the organism.…”

mentioning

confidence: 99%

In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori)

Caekenberghe

Breyssens

1987

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro interactions between bismuth subcitrate and a variety of antimicrobial agents against 12 Campylobacter pyloridis (C. pylorn) isolates were studied by the agar dilution checkerboard technique. The combination of bismuth subcitrate with the older quinolone, oxolinic acid, produced synergistic activity against all strains. This observation, however, could not be extended to the (aryl) fluoroquinolones, norfloxacin, ofloxacin, and difloxacin, since synergy was rare or absent when bismuth subcitrate was combined with these antibiotics. Among the other antimicrobial agents tested, rifampin and the beta-lactams frequently showed synergistic interactions with bismuth subcitrate. Nifuroxazide, a nitrofuran which is not significantly absorbed, showed MICs for C. pyloridis similar to those of bismuth subcitrate.Antimicrobial chemotherapy is helping to clarify the role of Campylobacter pyloridis (C. pylori) in the pathogenesis of gastritis. Histological studies have demonstrated that gastritis is cured after the organism is eradicated from the gastric mucosa (6, 9).A variety of antimicrobial agents display good activity against C. pyloridis in vitro (1,5,8). Yet when tested as single agents in clinical studies, they do not succeed in eradicating the organism. Failure of therapy and relapse are very common (10). The reason for this discrepancy between in vitro and clinical results has not been established. Possible explanations are poor penetration of the compounds in gastric mucus, destruction at acid pH, or both. The best results so far have been achieved with the combination of a nonabsorbed agent with topical activity, colloidal bismuth subcitrate, and a well-absorbed agent with systemic activity, amoxycillin (10). But clearly, therapy for C. pyloridisassociated infections still is suboptimal.The purpose of this study was to select, on the basis of synergistic activity in vitro, advantageous partner compounds for bismuth salts for combination therapy against C. pyloridis.The antibiotics (ampicillin, cefaclor, difloxacin, erythromycin, metronidazole, minocycline, nifuroxazide, nitrofurantoin, norfloxacin, ofloxacin, oxolinic acid, polymyxin B, rifampin, and tobramycin) were provided by the manufacturers. Bismuth subcitrate was obtained from Gist-Brocades nv, Delft, The Netherlands.The organisms which were tested were 12 recent C. pyloridis isolates obtained from antrum biopsies from patients at the University Hospital, Antwerp, Belgium. One isolate from each patient was tested. The identification of isolates was based on standard biochemical tests (7).Antibiotic solutions were prepared in appropriate buffer solutions, distilled water, or both. Bismuth subcitrate powder was brought into colloidal suspension in 1 N NaOH and further diluted in distilled water.Antibacterial activity was determined by the agar dilution technique, with Mueller-Hinton agar (GIBCO Diagnostics, Madison, Wis.) supplemented with 10% sterile defibrinated * Corresponding author. horse blood to support growth of the organism. The inoculu...

show abstract

Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents

Cited by 106 publications

References 17 publications

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Helicobacter pyloriDetection and Antimicrobial Susceptibility Testing

In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori)

Contact Info

Product

Resources

About